Advised BioMérieux on its €1.1 billion Initial Public Offering (IPO) on Euronext Paris, managing the strategic transition from a private family-held entity to a publicly traded leader in the diagnostics sector. The deal included overseeing the global investor roadshow, defining valuation criteria, and coordinating the pricing and allocation process to successfully secure a diversified capital base for the company’s international expansion.